AbbVie is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.
Through its partnership with Valkai, AbbVie will deploy purpose-built AI capabilities designed to improve efficiency across targeted areas of clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines.
AI plays an important role at AbbVie in advancing scientific innovation, strengthening connected operations and improving how medicines are discovered, developed and delivered to patients. Its partnership with Valkai builds on AbbVie's strong foundation of applying AI across R&D, helping to further scale data-driven insights and innovation.
"At AbbVie, we are focused on applying AI where it can create meaningful impact for our business and, ultimately, for patients," said Nicholas Donoghoe, executive vice president, chief business and strategy officer, AbbVie. "As clinical data continues to grow in volume and complexity, partnerships like Valkai help us generate insights faster and enable our teams to spend more time on the decisions that matter most. By combining advanced AI capabilities with human expertise, we can help bring new medicines to patients more efficiently."
Across AbbVie, AI serves as a critical tool to complement employee insight, enabling teams to drive strategic priorities and expedite delivery of medicines to patients, while maintaining a strong commitment to responsible and ethical use.
"We're delighted to partner with AbbVie, combining advanced AI capabilities with deep scientific expertise," said Vignesh Rajendran, co-founder and chief executive officer, Valkai. "AbbVie's scale, innovation and unwavering focus on patients make this the kind of partnership that can turn bold ambition into meaningful impact."